FDA Approves Botanix Pharmas New Underarm Sweat Drug

Botanix Pharmaceuticals (ASX: BOT) announced FDA approval for its drug Sofdra, a sofpironium gel, marking its transition from development to a revenue-generating company. Sofdra, approved at a 12.45% concentration, is the only FDA-approved product for treating excessive underarm sweating in the US, a condition affecting about 10 million people.

The drug reduces sweating by targeting eccrine glands. Botanix anticipates revenue from US sales starting in Q4 of 2024. The President of the American Academy of Dermatology, David Pariser, hailed the approval as significant for the hyperhidrosis community due to the drug’s effectiveness and ease of use. Botanix’s stock was last traded at 34 cents per share.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com